In Vivo Correlates of Central Serotonin Function after High-Dose Fenfluramine Administration

Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users

Despite evidence that +/-3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') causes persistent alterations to the serotonergic system of animals, evidence for long-term neurological effects of ecstasy/MDMA in humans remains equivocal. The current study assessed serotonin functioning of nine male and 11 female recreational ecstasy polydrug users by measuring neuroendocrine (prolactin, cortisol) responses to pharmacological challenge with the selective serotonin reuptake inhibitor citalopram, compared with nine male and five female cannabis polydrug users and 11 male and 11 female non-drug using controls. A single-blind, randomised, placebo-controlled design was used. Subjective responses, other substance use, mood, personality traits and demographic variables were measured to control for potentially confounding variables. There were no significant differences between ecstasy polydrug users, cannabis polydrug users and non-drug using controls in neuroendocrine or subjective responses to serotonergic challenge, and there were no sex by drug group interactions. There was no relationship between extent of ecstasy use and neuroendocrine functioning, alone or in combination with potential confounding variables. Subjective responses to the pharmacological challenge (nausea, tremor, dry mouth), novelty seeking and lifetime dose of alcohol were the only variables that contributed to one or more of the neuroendocrine outcome variables. These data do not support the premise that recreational ecstasy/MDMA use results in measurable impairment of serotonergic control of endocrine activity.

Characterization of D-fenfluramine-induced hypothermia: evidence for multiple sites of action

The effects of D-fenfluramine on core body temperature has been largely investigated under conditions of either high or low ambient temperature, whereas little research has focused on this response under normal environmental conditions. Moreover, there has been neglect in research on the mechanisms underlying changes in body temperature. In this study, we demonstrate that D-fenfluramine (5 and 10 mg/kg) induces a sustained decrease in body temperature in the rat under normal ambient temperatures. Pre-treatment with the selective serotonin reuptake inhibitor sertraline (5 mg/kg), the full 5-HT(1A) receptor antagonist 4-fluoro-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2-pyridinyl benzamide], WAY 100635 (0.15 mg/kg) and the 5-HT(2C) receptor antagonist benzofuran-2-carboxamidine, RO 43-0440 (2.5 mg/kg) blocked D-fenfluramine-induced hypothermia. Depletion of 5-hydroxytryptamine (5-HT) stores following treatment with the serotonergic neurotoxin parachlorophenylalanine reversed the initial hypothermic effects of D-fenfluramine but not the later effects, as D120 min post-challenge) in animals pre-treated with parachlorophenylalanine. Such findings are consistent with a requirement for D-fenfluramine uptake into 5-HT neurons followed by release of 5-HT from intracellular stores and stimulation of post-synaptic 5-HT receptors to reduce body temperature. The hypothermic response to D-fenfluramine was potentiated by ketanserin pre-treatment 30 min post-challenge but then antagonized at later time intervals. Pre-treatment with the dopamine, D(2) antagonist, haloperidol (1 mg/kg) and sulpiride (30 mg/kg) had a similar effect in blocking the hypothermia as WAY 100635, suggesting a role for dopamine D(2) receptors in the response. Pre-treatment with the alpha(2)-adrenoceptor antagonist yohimbine failed to block the hypothermic response. These results suggest multiple sites of action mediating D-fenfluramine-induced hypothermia and may be the result of a combined effect of D-fenfluramine and its active metabolite norfenfluramine affecting not only the release of 5-HT but also stimulation of post-synaptic receptors.

5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response

Since its discovery 50 years ago, the role of the indoleamine 5-HT (5-hydroxytryptamine; serotonin) in the pathogenesis of depression and in the mechanism of action of antidepressant drugs has been the subject of considerable research. Advances in molecular biology and radioligand techniques have led to the functional characterisation of at least 14 serotonin receptor subtypes. This classification has led to the development of selective compounds that have aided in the efforts of dissecting the complex role of 5-HT in depression and in mediating the antidepressant response. This review focuses largely on novel strategies of targeting specific 5-HT receptors subtypes, especially the presynaptic 5-HT(1A) and 5-HT(1B/1D) receptors. These subtypes are of primary importance in that they control the firing of the 5-HT neuron and the release of 5-HT. In addition, a number of postsynaptic 5-HT receptors have been shown to be dysfunctional in depression and are also potential targets for a number of antidepressants. We conclude that selective targeting of 5-HT receptors may lead to a faster acting and more efficient antidepressant response. Copyright 2000 John Wiley & Sons, Ltd.

Effects of fenfluramine on body weight, feed intake, and reproductive activities of broiler breeder hens

Inherited overfeeding and fattiness reduce laying performance in broiler breeder pullets. Although feed restriction is used to compensate for overeating and weight gain, this management practice leads to increases in BW variation, labor cost, and bird stress. Dietary supplementation of anorectic agents, such as fenfluramine, may be an alternative. Anak female prebreeder hens (19 wk of age; n = 10 per group) were treated as follows: daily oral administration of 5, 10, 20, or 40 mg DL-fenfluramine/kg BW or saline with food provided for ad libitum intake or administration of saline and feed restriction. Daily feed intake (FI), laying rate, egg composition, and BW were measured. At 40 wk of age, adipose tissue and ovary weights were measured. Fenfluramine depressed (P < 0.05) BW and FI in a dose-dependent manner, but was less effective in reducing BW than feed restriction. Suppression of FI occurred in two phases: a dynamic phase, coinciding with the rapid growth phase, during which FI declined progressively and a static phase during which FI reached a plateau at a significantly low level until the end of the experimental period. Egg production peaked first in saline-treated hens fed for ad libitum intake, but soon after started to decline. In all fenfluramine-treated and feed-restricted hens, egg production peaked 3 to 4 wk later and remained high until the end of the experiment. There were no differences in egg and egg component weights among the experimental groups. Abdominal adipose tissue weight was reduced by fenfluramine in a dose-related manner, and its weight in the group treated with the highest dose was similar to that of feed-restricted hens. In these two groups, ovarian weight was significantly higher than in the saline-treated hens fed for ad libitum intake, and a small, nonsignificant increase in ovary size was observed in groups treated with the two median doses of fenfluramine. The effect of fenfluramine on egg production was similar to that of feed restriction, but it was not dose-dependent and, thus, not directly related to its leaning effect. In broiler breeder hens, oral fenfluramine may be used for chemical feed restriction and diminution of fattiness without reducing egg production relative to manually feed-restricted hens.